Poseida Therapeutics (CDMO)

San Diego, CA
Hybrid — also manufactures internal programs
CAR-T Cell Therapy Gene Editing
No confirmed program data — ClinicalTrials.gov verification pending · Last scored 2026-09-07
58.7
Signal Score
○ FDA Inspections ✓ Clinical Trials (6) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Poseida Therapeutics (CDMO)

Signal Score
58.7/100 (as of 2026-09-07)
Quality Compliance
Assessment pending
Headquarters
San Diego, CA
Modalities
CAR-T, Cell Therapy, Gene Editing
Active Programs
Data pending
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Poseida Therapeutics (CDMO)

Hybrid developer + CDMO.

Signal Score & Pillar Breakdown

Scores are being republished. Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations 51.7
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, Gene Editing
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
NCT06014762 P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT04960579 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT05239143 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of... PHASE1 Active Not Recruiting
NCT04249947 P-PSMA-101 CAR-T Cells in the Treatment of Subjects With... PHASE1 Terminated
NCT03741127 Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 PHASE1 Active Not Recruiting
NCT03288493 P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With... PHASE1/PHASE2 Terminated
Source: ClinicalTrials.gov · Retrieved Oct 06, 2026
Financial Stability 68.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity 58.0
Profile-based capacity assessment

Frequently Asked Questions About Poseida Therapeutics (CDMO)

How many clinical programs is Poseida Therapeutics (CDMO) linked to?
Poseida Therapeutics (CDMO) is associated with 6 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Poseida Therapeutics (CDMO)'s CDMO Signal Score?
Poseida Therapeutics (CDMO) has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Poseida Therapeutics (CDMO) for a manufacturing program?
Use the free AI matchmaker to compare Poseida Therapeutics (CDMO) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → Gene Editing CDMOs →

Similar CDMOs

Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.3
CAR-T, Cell Therapy, iPSC, Gene Editing
GenScript
Piscataway, NJ (US HQ); Nanjing, China (primary operations)
Signal Score: 64.0
CAR-T, Cell Therapy, Gene Editing
CTMC
Houston, TX
Signal Score: 63.0
CAR-T, Cell Therapy, Gene Editing
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 83.9
CAR-T, Cell Therapy